AMRX FY 2023 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

FY 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2.4B+8.2% YoY

Gross Profit

$864M36.1% margin

Operating Income

$204M8.5% margin

Net Income

-$84M-3.5% margin

EPS (Diluted)

$-0.48

Cash Flow

Operating Cash Flow

$346M

Free Cash Flow

$276M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$3.5B

Total Liabilities

$3.4B

Stockholders' Equity

$20M

Cash & Equivalents

$92M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.4B	$2.2B	+8.2%
Gross Profit	$864M	$791M	+9.1%
Operating Income	$204M	-$95M	+315.3%
Net Income	-$84M	-$130M	+35.4%